Issue link: https://www.e-digitaleditions.com/i/1462155
46 Pharmaceutical Technology QUALITY AND REGULATORY SOURCEBOOK EBOOK MARCH 2022 P h a r mTe c h . c o m Regulations: Supply Chain D isruptions in the bio/pharmaceutical supply chain that impact capacity and capabilities result in longer lead times for drug products, according to Ari Ojinaka, pro- duction manager at Astrea Bioseparations. The past two years of the COVID-19 pandemic have highlighted the impor- tance of a healthy supply chain. "Through the pandemic, we have witnessed a significant reduction in inter-country transportation of goods and services and in-country COVID-19 restriction impacting capacity and capabilities to manufacture," says Ojinaka. Pharmaceutical Technology spoke with Ojinaka as well as Steve Kirk, vice-president Global Procurement, Catalent; Vincent Col- icchio, vice-president, Supply Chain and External Manufacturing, Dr. Reddy's Laboratories; and Hamilton Lenox, senior vice presi- dent–Business Development & Operations at LGM Pharma about the impact of COVID-19 on the supply chain and what companies can do to ensure the quality of their products. The consequences of supply chain interruptions PharmTech: How can supply chain interruptions impact pharmaceuti- cal manufacturing and drug availability? Colicchio (Dr. Reddy's Laboratories): Generally speaking, supply chain interruptions are one of the biggest issues the pharma industry faces at this time. The main stress points are transportation and labor availability. COVID has reduced the cargo capacity globally for all modes of transportation, which in turn has created a domino effect for many of the other functions within the supply chain industry. With reduced transportation capacity, drug suppliers are now forced Supply Chain Considerations for Ensuring Quality Susan Haigney Disruptions in the bio/ pharmaceutical supply chain can have serious impacts on the quality and availability of life-saving medicines. WRIGHTSTUDIO - STOCK.ADOBE.COM